Phase 1 Start
EXEL: Phase 1 Start: A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Sol
September 30, 2026 · xl092. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2026
- Company
- EXELIXIS, INC. (EXEL)
- Drug
- xl092
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Sol
- Company
- EXELIXIS, INC. (EXEL)
- Drug
- xl092
- Indication
- Cancer; Pediatric Cancer